Fourth Quarter Financial Highlights - Total revenue was $63.6 million. - Net product sales were $50.0 million. Sales of our Proprietary Medical Products were $18.3 million, or 37% of total product sales. Sales of our Base Medical Products were $31.7 million, or 63% of total product sales. - Royalty revenue was $13.5 million. - Research and development expenses were $6.2 million. - Selling, general and administrative expenses were $22.4 million. - Net loss and net loss per share were $15.6 million and $0.18, respectively. - As of December 31, 2009, cash and short-term investments were $57.3 million and net debt was $517.7 million. Selected Non-GAAP Financial Measures - Certain financial measures in this press release are prepared in accordance with United States Generally Accepted Accounting Principles ("GAAP"). In addition, certain financial measures presented below and in the appendix to this press release are non- GAAP, or adjusted, financial measures that exclude certain items. Management uses certain non-GAAP, or adjusted, financial measures to establish operational goals, and believes that these measures may assist investors in evaluating the results of our business and analyzing the underlying trends in our business over time. Investors should consider these non-GAAP adjusted financial measures in
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved